Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • tu.le
    replied
    I've tried to map sub-sequences after the flipping point separately but the performance was really bad (~0.6%). It seems that they were miss-created even their quality report was quite nice. Also, this is newly created data thus it should be a good idea to ask the provider. Anyway, thank you all for helpful suggestion.

    Leave a comment:


  • westerman
    replied
    Originally posted by mastal View Post
    How long ago was this sample run?
    It can't be that long ago with reads extending out to 170+ bases. Unless ...
    ... R1 and R2 were joined together, as someone has already mentioned above.
    Which is my feeling as well.

    Leave a comment:


  • mastal
    replied
    How long ago was this sample run?

    Note that FastQC is assuming that the format is Illumina 1.5.

    The current version is Illumina 1.9, so FastQC may be rendering the base qualities incorrectly.

    The shape of the per base sequence qualities plot looks like what you would expect if R1 and R2 were joined together, as someone has already mentioned above.

    Leave a comment:


  • GenoMax
    replied
    There seems to be some issue with this run if both control (non-methylated) and treated samples show this pattern. My hunch is that the problem is not related to your samples. You should ask the sequence provider if there was a technical glitch of some kind during the run. It could very well be a bad kit or a problem with the instrument.

    Leave a comment:


  • biznatch
    replied
    I've run about two dozen RNA- and ChIP-seq samples and never seen the quality dip like that in the middle, are you sure that is normal? It's still in the green, it just looks weird to me.

    Leave a comment:


  • tu.le
    replied
    @Gringer: Thanks for your suggestion, I'll try to see whether the second halves can be mapped or not.
    @GenoMax: This phenomenon was seen for both case and control samples but I don't really know the reason. The quality plots are quite normal, as below attachment. Thanks.
    Attached Files

    Leave a comment:


  • GenoMax
    replied
    Have you asked your sequence provider if there were other samples on the flowcell which did or did not show this particular phenomenon? That does look odd.

    How about the quality plots? Do they look ok?

    Leave a comment:


  • gringer
    replied
    The flipping is very suspicious. I would certainly treat the halves separately, but first try and split the reads at the halfway point and map both halves. If you find that the second half doesn't map anywhere (including primer sequences), then maybe it will be appropriate to drop those bases.

    Finding the cause of that flipping would be great, but that's probably going to be quite a challenge.

    Leave a comment:


  • tu.le
    replied
    Hi Gringer,
    As far as I know this is not PE but SE library. Also, the bias toward low GC content may be caused by BS treatment. Whether removal of bases after flipping point decreases the coverage and/or affects downstream analysis?

    Leave a comment:


  • gringer
    replied
    These wouldn't happen to be paired-end reads separated by a barcode sequence around 80bp would they? The base proportions for complementary bases flip after that point.

    Despite that, the zero counts are a little odd -- A GC content of 10% seems a little on the low side.

    Leave a comment:


  • tu.le
    started a topic Strange FastQC "Per base sequence content report"

    Strange FastQC "Per base sequence content report"

    Hi,
    I would like to ask if any one experienced with the kind of "Per base sequence content" graph below generated by FastQC? and what does it mean? If only the first ~80 bases are kept does it decrease the coverage and affect downstream analysis?
    Thanks in advance,
    Attached Files

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Yesterday, 11:13 AM
0 responses
14 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, Yesterday, 10:48 AM
0 responses
13 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
32 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
40 views
0 reactions
Last Post SEQadmin2  
Working...